Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck
Sponsor: Bristol-Myers Squibb
Listed as NCT03521570, this PHASE2 trial focuses on Recurrent Head and Neck Squamous Cell Carcinoma and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 13 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Mar 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Jun 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Emory University
- Medical College of Wisconsin
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .